Saturday 17 October 2026
Export ZTS’s income statement to Excel — free account
Zoetis Inc.
ZTS Healthcare Drug Manufacturers Specialty & Generic
Zoetis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.5 billion, up 2.28% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 2.48%, free cash flow grew 17.4% and total debt rose 37.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for ten consecutive years, revenue growth for ten; insiders bought in the last twelve months.
79.20
0.78
+0.99%
Follow ZTS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
24.63 | 20.87 | 19.57 | 11.82 |
P/S ratio |
6.90 | 5.89 | 5.24 | 3.15 | |
P/FCF ratio |
28.93 | 24.44 | 22.21 | 12.90 | |
P/Operating CF |
72.73 | 62.48 | 124.43 | 45.81 | |
P/B ratio |
12.01 | 16.34 | 15.43 | 9.53 | |
Price to Tangible BV |
40.66 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
7.58 | 6.73 | 6.12 | 4.07 | |
EV/EBITDA |
17.75 | 15.66 | 14.37 | 9.64 | |
EV/Operating CF |
24.40 | 21.95 | 20.91 | 13.64 | |
EV/FCF |
31.76 | 27.92 | 25.97 | 16.64 | |
Quick Ratio |
2.01 | 1.78 | 1.68 | 1.58 | |
Current Ratio |
3.64 | 3.12 | 3.15 | 3.08 | |
Net Debt/EBITDA |
4.67 | 6.82 | 7.57 | 7.05 | |
Debt/Assets |
46.63% | 58.37% | 59.69% | 60.01% | |
Debt/Equity |
1.31 | 2.65 | 2.80 | 2.87 | |
Asset Turnover |
0.64 | 0.64 | 0.65 | 0.64 | |
Operating CF/Net income |
1.24 | 1.43 | 0.67 | 0.95 | |
Capex/Depreciation |
(1.10) | (1.34) | (0.84) | (0.97) | |
Interest Coverage |
16.29 | 14.82 | 13.23 | 15.20 | |
Research and Development Expense of Revenue |
7.08% | 8.35% | 7.96% | 7.01% | |
Selling, General and Administrative Expense of Revenue |
24.13% | 25.51% | 25.99% | 23.99% | |
Intangible Assets out of Total Assets |
0.25 | 0.24 | 0.25 | 0.24 | |
Share Based Compensation of Revenue |
0.92% | 0.92% | 1.11% | 1.05% | |
Graham Net Nets |
(0.05) | (0.09) | (0.11) | (0.19) | |
Graham Number |
40.36 | 32.32 | 32.26 | 32.11 | |
Earnings Yield |
4.06% | 4.79% | 5.11% | 8.46% | |
Free Cash Flow Yield |
3.46% | 4.09% | 4.50% | 7.75% | |
Revenue per Share |
5.42 | 5.40 | 5.36 | 5.91 | |
Operating CF per Share |
2.01 | 2.01 | 0.95 | 1.57 | |
Capex per Share |
(0.30) | (0.37) | (0.24) | (0.28) | |
Free Cash Flow per Share |
1.71 | 1.65 | 0.71 | 1.29 | |
Cash per Share |
4.71 | 5.52 | 4.60 | 4.01 | |
Shareholders Equity per Share |
12.19 | 7.70 | 7.66 | 7.54 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
12.19 | 7.70 | 7.66 | 7.54 | |
Free Cash Flow |
756.00 | 731.00 | 301.00 | 539.00 | |
Working Capital |
4,776.00 | 4,600.00 | 4,421.00 | 4,295.00 | |
Capital Expenditures |
(135.00) | (162.00) | (100.00) | (116.00) | |
Net Current Asset Value |
(3,178.00) | (5,302.00) | (5,447.00) | (5,573.00) | |
EV/EBIT |
20.21 | 17.79 | 16.32 | 10.95 | |
Capex to Sales |
0.06 | 0.07 | 0.04 | 0.05 | |
Price to Operating Income |
19.61 | 16.61 | 14.92 | 9.10 | |
| Other line items | |||||
Average Receivables |
1,476.00 | 1,362.50 | 1,433.50 | 1,555.50 | |
Average Payables |
407.00 | 439.00 | 463.50 | 480.00 | |
Average Inventory |
2,440.50 | 2,385.00 | 2,457.50 | 2,506.50 | |
Average Assets |
14,758.00 | 14,863.50 | 14,626.00 | 14,778.00 | |
Average Common Equity |
5,316.00 | 4,092.50 | 3,944.00 | 4,062.50 |
Columns are period end dates